Floatz logo

EF-5

Regional Gastrointestinal Carcinoid Tumor

National Cancer Institute (NCI)Small moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Regional Gastrointestinal Carcinoid Tumor cohort.

Asset / SponsorPhaseRating
Romidepsin
National Cancer Institute (NCI)
Phase 2CCC
Temsirolimus
University of Southern California
Phase 1CC
Vinorelbine
University of Southern California
Phase 1CC
LUTETIUM TEXAPHYRIN
National Cancer Institute (NCI)
N/AD
Cediranib
National Cancer Institute (NCI)
N/AD

Same molecule, other indications

EF-5 is also rated in:

cervical cancerDormant
CC
Indicative ·
47 / 100
View asset →
primary peritoneal carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
Stage I Ovarian Epithelial CancerDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →